Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria.
Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8530, Japan.
Immunotherapy. 2023 Aug;15(12):933-943. doi: 10.2217/imt-2022-0309. Epub 2023 Jul 6.
We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.
我们旨在回顾减少非肌肉浸润性膀胱癌（NMIBC）患者卡介苗（BCG）灌注剂量或次数的证据。根据荟萃分析报告的首选项目进行了文献检索。总体而言，分别有 15 项和 13 项研究适合定性和定量综合分析。在 NMIBC 患者中，降低 BCG 灌注的剂量或次数会增加复发的风险，但不会增加进展的风险。与标准剂量 BCG 相比，降低 BCG 的剂量会降低不良事件的风险。基于肿瘤学疗效，标准剂量和 BCG 次数更适合 NMIBC 患者；然而，对于患有严重不良事件的患者，可以考虑使用低剂量 BCG。
